| __timestamp | BioCryst Pharmaceuticals, Inc. | United Therapeutics Corporation |
|---|---|---|
| Wednesday, January 1, 2014 | 7461000 | 381287000 |
| Thursday, January 1, 2015 | 13047000 | 452612000 |
| Friday, January 1, 2016 | 11253000 | 316800000 |
| Sunday, January 1, 2017 | 13933000 | 330100000 |
| Monday, January 1, 2018 | 29514000 | 265800000 |
| Tuesday, January 1, 2019 | 37121000 | 336200000 |
| Wednesday, January 1, 2020 | 67929000 | 423900000 |
| Friday, January 1, 2021 | 118818000 | 467000000 |
| Saturday, January 1, 2022 | 159371000 | 487000000 |
| Sunday, January 1, 2023 | 213894000 | 477100000 |
Infusing magic into the data realm
In the competitive world of biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for financial health. Over the past decade, United Therapeutics Corporation and BioCryst Pharmaceuticals, Inc. have shown contrasting trends in their SG&A expenses. From 2014 to 2023, United Therapeutics consistently maintained higher SG&A expenses, peaking at approximately $487 million in 2022. This reflects their expansive operational strategies and robust market presence. In contrast, BioCryst Pharmaceuticals, while starting with a modest $7 million in 2014, saw a dramatic increase, reaching $214 million by 2023. This 28-fold rise highlights their aggressive growth and investment in administrative capabilities. The data underscores the strategic differences between these two companies, offering insights into their operational priorities and market strategies. As the biotech industry evolves, understanding these financial dynamics becomes essential for investors and stakeholders.
Operational Costs Compared: SG&A Analysis of Eli Lilly and Company and BioCryst Pharmaceuticals, Inc.
Selling, General, and Administrative Costs: Johnson & Johnson vs BioCryst Pharmaceuticals, Inc.
Biogen Inc. and BioCryst Pharmaceuticals, Inc.: SG&A Spending Patterns Compared
United Therapeutics Corporation vs Sarepta Therapeutics, Inc.: SG&A Expense Trends
Breaking Down SG&A Expenses: United Therapeutics Corporation vs Verona Pharma plc
United Therapeutics Corporation vs Ultragenyx Pharmaceutical Inc.: SG&A Expense Trends
Cost Management Insights: SG&A Expenses for United Therapeutics Corporation and Alkermes plc
Selling, General, and Administrative Costs: United Therapeutics Corporation vs Geron Corporation
SG&A Efficiency Analysis: Comparing Catalent, Inc. and BioCryst Pharmaceuticals, Inc.
Breaking Down SG&A Expenses: Pharming Group N.V. vs BioCryst Pharmaceuticals, Inc.
Breaking Down SG&A Expenses: Ionis Pharmaceuticals, Inc. vs BioCryst Pharmaceuticals, Inc.
Cost Management Insights: SG&A Expenses for Geron Corporation and BioCryst Pharmaceuticals, Inc.